Osteonecrosis of the jaws associated with denosumab : study of clinical and radiographic characteristics in a series of clinical cases by Tofé, Victoria I. et al.
J Clin Exp Dent. 2020;12(7):e676-81.                                                                                                                                                                   
e676
Journal section: Oral Medicine and Pathology                      
Publication Types: Research
Osteonecrosis of the jaws associated with denosumab: Study of clinical and 
radiographic characteristics in a series of clinical cases
Victoria I. Tofé 1, Leticia Bagán 1, José V. Bagán 2 
1 Oral Medicine, University of Valencia, Spain
2 Oral Medicine of the University of Valencia, Department of Stomatology and Maxillofacial Surgery, University of Valencia, Ge-
neral University Hospital, Valencia, Spain
Correspondence:





Background: The objective of this study was to describe the clinical and radiographic characteristics of our series 
of medication-related osteonecrosis of the jaws (ONJ) associated with denosumab.
Material and Methods: We presented 15 cases of ONJ associated with denosumab; 11 received treatment for their 
osteoporosis and four for cancer treatments. We recorded the most frequent clinical findings, symptoms and radio-
graphic characteristics in our patient group, as well as local and systemic contributing factors.
Results: The mean time of treatment with denosumab was 23.83 ± 12.84 months. 40% of the patients had a previous 
history of treatment with bisphosphonates. The most common local factor was tooth extraction (11 cases; 73.3%), 
and in most cases there was necrotic bone exposure (13/15, 86.67%). Osteolysis, bone sclerosis and cortical erosion 
were the most common radiographic findings. Stage 1 was the most frequent, present in 60% of the cases.
Conclusions: In our patient group, most were in the early stages of ONJ.




The first antecedent reported in the literature of maxi-
llary osteonecrosis (ONJ) dates back to the 19th century 
and describes a pathology called “phosphorous necro-
sis” or “phossy jaw”, associated with phosphorus poiso-
ning, with signs and symptoms similar to the ONJ (1).
In 2007, the American Association of Oral and Maxillo-
facial Surgeons (AAOMS) (2) defined osteonecrosis as 
an exposure of necrotic bone in the maxillofacial region 
that persists for more than 8 weeks in patients who are 
receiving or have received treatment with bisphospho-
nates and who have no previous history of radiothera-
py in the jaws. However, in 2014, due to the increasing 
number of cases of osteonecrosis associated with other 
antiresorptive therapies -denosumab- and antiangioge-
nic therapies, the term “Osteonecrosis of the jaws rela-
ted to medications” was proposed (3).
Both bisphosphonates and denosumab are predomi-
nantly indicated for the reduction of the risk of skeletal 
complications in patients with bone loss resulting from 
long-term cancer treatment, osteoporosis, or malignant 
bone disease (4).
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Although both drugs have similar therapeutic indica-
tions, their mechanism of action is significantly different 
(5). While bisphosphonates must be internalized in os-
teoclasts to exert their effect on cells, denosumab acts in 
the extracellular environment (6).
In May and June 2010, the European Commission (EC) 
(European Medicines Agency, 2015) and the Food and 
Drug Administration of the United States (FDA) (Food 
and Drug Administration, 2010) approved the marketing 
and use of Prolia® for the treatment of osteoporosis in 
women and men with high risk of fractures, as well as 
for the treatment of osteopenia associated with hormo-
nal suppression in male patients with prostate cancer. Its 
dose is 60 mg subcutaneously every 6 months (7).
In contrast, Xgeva® was authorized for commercializa-
tion in July 2011, being indicated for the prevention of 
osteoarticular pathological events (pathological fractu-
re, bone radiotherapy, spinal cord compression or bone 
surgery) as well as in adults with bone metastases from 
solid tumors or giant cell bone tumors. Its usual dose is 
120 mg subcutaneously every 4 weeks (8).
Already in 2010, Taylor et al. (9) published the first report 
that described a case of ONJ associated with denosumab 
and, since then, more and more clinical studies have been 
published that describe this complication.
In cancer patients exposed to denosumab, the risk of ONJ 
varies from 0.7 to 1.9% (70 to 90 cases per 10,000 pa-
tients) (3) and they have been reported to have a risk of 
developing ONJ similar to that of acid zoledronic (10).
In patients with osteoporosis treated with denosumab, 
the incidence of ONJ is lower, resulting in an even lower 
frequency of 0.04% (four cases per 10,000 patients) (3).
However, the number of cancer and non-cancer patients 
treated with ONJ-related medications and, therefore, the 
number of potentially adverse events seems to be cons-
tantly increasing (11).
Given this, our work aims to describe fifteen cases of 
ONJ in patients who have been treated with denosumab, 
analyze their clinical and radiographic characteristics, 
as well as the systemic and local factors that favor the 
development of these lesions.
Material and Methods
We present a series of fifteen patients with ONJ who re-
ceived denosumab for osteoporosis or cancer causes. Of 
these, most had osteoporosis (11 cases, 73.3%) which 
was treated with Prolia ®. The remaining 26.7% (4/15) 
were being treated with Xgeva ® due to cancer causes.
To do this, we follow the ethical guidelines of the Decla-
ration of Helsinki. The study was approved by the Ethics 
Committee for Human Research of the Commission for 
Ethics in Experimental Research of the University of 
Valencia (Ref. H1441967790259).
The search system for the collection of cases was throu-
gh the database of the Stomatology and Maxillofacial 
Surgery Service of the General University Hospital of 
Valencia, where those patients who had been treated 
with drugs whose active substance was denosumab - 
Prolia or Xgeva- were selected and who were diagnosed 
with ONJ from a clinical and radiographic point of view.
For the diagnosis of ONJ patients, the criteria described 
by Ruggiero et al. (3) were used.
Inclusion criteria were: patients who presented at least 
one area of mandibular / maxillary osteonecrosis and 
who were previously or currently treated with denosu-
mab.
The exclusion criteria were: patients with bone lesions 
due to a maxillary metastasis or who had been irradia-
ted in the cervical-facial area, those who had previously 
received denosumab but did not develop ONJ, and pa-
tients who developed ONJ by other antiresorptive and / 
or antiangiogenic agents.
For each patient we recorded the age, sex, type of disea-
se for which denosumab was indicated, the drug admi-
nistered (Prolia or Xgeva), the duration of treatment, the 
presence of concomitant treatment with other drugs, the 
presence of comorbidities and of prior treatment with bis-
phosphonates and local predisposing factors of ONJ.
Regarding the clinical aspect, we considered the location 
of the ONJ (upper jaw, jaw or both), the number of expo-
sures, the maximum size of the exposures, the presence 
of pain, infection, suppuration, intraoral fistula, extraoral 
fistula and bone exposure (Fig. 1). Finally, we classified 
the 15 cases in the stages proposed by Ruggiero et al. (3).
Fig. 1: Osteonecrosis due to denosumab in the jaw in case 2.
For the radiographic study, orthopantomographs and 
computed tomography (CT) of the patients were con-
sidered (Figs 2,3). The presence of orosinusal involve-
ment, osteolysis, bone sclerosis, erosion of the cortex, 
decrease of the mandibular canal, thickening of the man-
dibular cortex, mandibular fracture and bone sequestra-
tion were recorded.
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Fig. 2: Orthopantomography of osteonecrosis in case 5.
Fig. 3: Computed tomography with evident mandibular osteolysis 
in case 6.
As the series consisted of only 15 cases, the statistical 
analysis involved only the descriptive aspects of the 
sample, calculating the mean and standard deviation for 
the quantitative variables and the frequency and per-
centage for the categorical variables. For this we used 
the statistical software SPSS v. 25 for Microsoft (IBM 
Corp., New York, NY; formerly SPSS Inc., Chicago, IL).
Results
The average age of our fifteen patients was 74.27 ± 9.47 
years; with an age range between 57 and 89 years. Wo-
men predominated in the sample (80%).
The mean treatment time with denosumab was 30.75 ± 
9.32 months for Prolia and 10 ± 4.4 months for Xgeva. 
40% of the patients (6/15) had received prior therapy 
with oral and intravenous bisphosphonates (Table 1).
In nine of the 15 cases (60%), the ONJ was located in 
the jaw, and the most common local factor was tooth ex-












Disease Osteoporosis: 11 cases (73.3%)
Breast cancer: 3 cases (20%)
Prostate cancer: 1 case (6.7%)
Drug Prolia: 11 cases (73.3%)



























Table 1: General characteristics in our series of 15 patients.
sociated with the placement of dental implants and two 
due to spontaneous causes. In six cases (40%) there was 
pain, two (13.3%) had an intraoral fistula, and necrotic 
bone exposure was presented in 13 cases (86.7%).
Stage 1 of ONJ was the most frequent since it occurred 
in nine cases (60%) (Table 2).
Regarding the radiographic study, we found that the 
majority of the patients had bone lysis (12 cases, 80%), 
bone sclerosis (10 cases, 66.7%) and cortical erosion (10 
cases, 90.9%). There was presence of bone sequestration 
in four cases (26.7%) (Table 3).
Discussion
Denosumab is a monoclonal antibody that acts by inhi-
biting osteoclast activity, reducing bone resorption and 
increasing bone density (4).
Specifically, denosumab prevents RANKL from binding 
to its receptor, RANK, in the osteoclast cell membrane 
and osteoblastic precursors, thereby inhibiting the deve-
lopment, activation and survival of osteoclasts (5).
It is important to note that most of the cells that produce 
RANKL also produce a RANK receptor, osteoprotege-
rin (OPG), which acts as an antagonist of RANK signa-
ling and osteoclastogenesis by eliminating RANKL in 
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Max. size exposures (mm) 13.20± 6.85
Pain 6 cases (40%)
Infection 5 cases (33.3%)
Suppuration 2 cases (13.3%)
Intraoral fistula 2 cases (13.3%)
Extraoral fistula 0 cases (0%)










Table 2: Clinical characteristics in our series of 15 patients.
Radiographic characteristics Cases (15)
Orosinusal involvement 1 case (6.7%)
Osteolysis 12 cases (80%)
Bone sclerosis 10 cases (66.7%)
Erosion of the cortex 10 cases (90.9%)
Decreased mandibular canal 1 case (6.7%)
Thickening of the mandibular cortex 1 case (9.1%)
Mandibular fracture 0 cases (0%)
Bone sequestration 4 cases (26.7%)
Table 3: Radiographic characteristics in our series of 15 patients.
the extracellular environment. The relationship between 
RANKL and OPG determines the level of RANK acti-
vation and, therefore, the degree to which osteoclastoge-
nesis is activated (5).
Consequently, the differentiation and function of os-
teoclasts are regulated by the balance between RANKL 
and OPG produced by osteoblasts and mesenchymal 
cells (13).
By joining RANKL in a similar way to OPG, denosumab 
prevents the interaction of RANKL and RANK, which 
translates into an inhibition of bone resorption (14).
Our series of osteonecrosis of the jaws associated with 
denosumab developed with greater prevalence in fema-
le patients (80%), with osteoporosis, who were under 
treatment with Prolia (73.3%). This coincides with other 
authors who report a greater predisposition in the female 
population, because the underlying diseases for which 
the agents are most frequently prescribed are osteoporo-
sis and breast cancer (3).
As in other publications, the average age of the patients 
with ONJ in our study was 74.27 years ± 9.47 (15).
According to some authors, the risk of ONJ seems to be 
independent of the number of doses of denosumab or the 
duration of treatment (15). However, this has yet to be 
ratified by more research. The mean treatment time with 
denosumab in our case series was 23.8 ± 12.8 months.
It has been described that ONJ is a multifactorial disea-
se since systemic and local factors are involved in its 
development. Within the systemic factors, it has been 
reported that certain comorbidities and the use of conco-
mitant medications may increase the risk of ONJ, such 
as diabetes, anemia, chronic corticosteroid therapy, an-
tiangiogenic and bisphosphonates therapy, among others 
(16). Of the 15 patients in our study, only one (6.7%) had 
diabetes and two (13.3%) had anemia.
Regarding the simultaneous use of other drugs and de-
nosumab, Saad et al. in 2012 (17) described that an as-
sociation can be found between the development of ONJ 
and the use of corticosteroids because they delay or hin-
der wound healing and favor the progression of lesions. 
In our study, four (26.7%) out of the 15 patients took 
corticosteroids and denosumab simultaneously.
Also, the use of other drugs such as antiangiogenic 
agents, when administered together with antiresorptives, 
is related to the appearance of osteonecrosis lesions sin-
ce they can suppress vascular regeneration and, subse-
quently, could promote ONJ (18). However, in our study 
no patient was registered to have been treated with an-
tiangiogenic agents.
We have assessed the possible contribution of previous 
bisphosphonate treatment, since it has been described 
that many patients who are currently under treatment 
with denosumab had previously been treated with bis-
phosphonates. This makes it difficult to establish which 
of the two drugs is more responsible for maxillary osteo-
necrosis, or if this could be the sum of both medications 
(19).
In 2018, Aljohani et al. (20) published a series of cases 
of ONJ by denosumab, where they reported that the pre-
vious use of bisphosphonates does not seem to affect the 
severity of ONJ by denosumab. In our study, 60% of the 
cases did not present prior treatment with bisphospho-
nates. However, it would be useful to conduct a larger 
sample study to conclude if both drugs together have a 
synergistic effect.
Dental extractions are considered to be the main trigger 
for developing ONJ (3). This coincides with our results, 
where we found that 73.3% of the cases had previously 
had at least one exodontics. We also observed that two 
patients developed osteonecrosis lesions after implant 
placement and that the appearance was spontaneous in 
two cases.
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Regarding the clinical characteristics of the ONJ asso-
ciated with denosumab, we have observed that the os-
teonecrosis lesion was mainly located in the jaw (60%), 
which coincides with other studies (3).
Bone exposure has been described as a key element for 
the diagnosis of ONJ (3). This coincides with our case 
series, where it was observed that bone exposure was the 
clinical manifestation that predominated in our sample 
(86.67%). Of our 15 patients, only 13.3% (2/15) had an 
intraoral fistula with suppuration and none had extraoral 
fistulas.
The most frequent stage was 1 (60%), so no signs of 
pain (40%) or infection (33.3%) were observed in most 
cases. This may be due to the fact that a large number of 
patients seek treatment after the onset of signs, such as 
when an exposed alveolar area persists after an extrac-
tion (21).
Although the diagnosis of ONJ is essentially based on 
the medical history and its clinical manifestations, the 
radiological findings are of great importance for the 
overall evaluation of the ONJ, determining the extent of 
the disease and being able to objectively define the area 
of necrosis, as well as for providing useful image data 
for subsequent surgical procedures. They are also very 
useful for monitoring the disease and for predicting its 
prognosis (22).
The imaging study of the ONJ shows manifestations 
such as lytic and / or sclera lesions, periosteal reactions, 
perforations or cortical thickening, mandibular fractu-
res, presence of exposed necrotic bone and narrower 
neurovascular channels such as the nasopalatin and 
mandibular canal (23).
It has been described that CT and conical beam CT are 
useful for patients with clinical suspicion of ONJ be-
cause they give us information of initial changes in the 
alveolar and cortical bones of the jaw, allowing us to 
evaluate the presence of exposed necrotic bone, fistula 
formation, periostic responses and affected teeth (24).
When performing the radiographic study on orthopanto-
mographs and CT scans of our patients, we observed 
that the majority presented bone lysis (80%), bone scle-
rosis (66.7%) and cortical erosion (90.9%) as the most 
frequent manifestations; this coincides with other case 
series of ONJ by denosumab.
Our work has some limitations since it is a retrospective 
study based on the analysis of a small sample size due 
to the low prevalence of the ONJ associated with deno-
sumab, and it should therefore be taken as a preliminary 
consideration to be verified with larger series of cases 
and multicentric studies.
Prospective, well-controlled and larger sample studies 
are required to obtain more consistent criteria, both for 
the clinical and radiographic aspects of the ONJ by de-
nosumab and for the local and systemic risk factors that 
favor its development.
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